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Introduction {#sec1}
============

An unbalanced production of interleukin-1 (IL-1) cytokines drives the immunopathology of several auto-inflammatory diseases ([@bib92]). As nearly all cells express the IL-1 receptor (IL-1R), IL-1 cytokines have the ability to influence innate and adaptive immunity and exert broad effects in the body. IL-1β is unique in the medical literature: while many human inflammatory diseases are caused by a host of cooperative inflammatory factors, mutations in genes controlling the expression of IL-1β cause a spectrum of life-threatening auto-inflammatory syndromes ([@bib14]). Monotherapies blocking IL-1β activity in patients with auto-inflammatory syndromes result in a rapid and sustained reversal of symptoms and severity ([@bib34]) and are currently the first line of intervention against these conditions. A growing bulk of evidence has now characterized other common inflammatory and metabolic conditions as responsive to IL-1β neutralization ([@bib32], [@bib33]). This was further validated by the results of the CANTOS Study, which showed that canakinumab, a humanized anti-IL-1β monoclonal antibody, significantly reduced the risk for recurrent cardiovascular events ([@bib84]) and indicated that IL-1β is associated with increased incidence of fatal lung cancer ([@bib85]).

The expression of IL-1 cytokines is tightly regulated. For instance, the production of some members of this family (e.g., IL-1β and IL-18) is restricted to immune cells. Furthermore, upon induction, these proteins are synthesized as inactive precursors in the cytosol, and a series of intracellular events is required for their maturation and release into the extracellular space. These events include the assembly of inflammasomes---intracellular protein complexes formed by a sensor---such as NLRP3, the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC), and the cysteine protease caspase-1 ([@bib58]). Upon activation, inflammasome sensors recruit ASC, which oligomerizes to form a micron-sized structure termed ASC speck, which recruits and activates caspase-1. Active caspase-1 processes pro-IL-1β and pro-IL-18 into their bioactive forms and drives an inflammatory cell death, termed pyroptosis, through gasdermin-D-induced membrane pore formation and leakage of cytosolic content ([@bib53], [@bib64]).

The majority of the studies on inflammasomes were performed *in vitro*, predominantly in monocultures of macrophages. Although this approach allowed the discovery of molecular mechanisms controlling inflammasomes, it underestimated the influence of other cell populations on the regulation of IL-1 cytokines *in vivo*. For instance, it has been recently discovered that T cells drive inflammasome-independent IL-1β production by dendritic cells (DCs) ([@bib49]).

Around one trillion platelets (150--450 × 10^9^/L) circulate in the blood of a healthy individual, outnumbering all other leukocytes in the vasculature by several folds. Platelets have been increasingly recognized for their roles in immunity ([@bib19], [@bib28], [@bib55], [@bib79]) and were reported to produce IL-1 cytokines ([@bib2], [@bib29], [@bib44], [@bib97]). More recently, they were reported to assemble inflammasomes ([@bib25], [@bib46]). Platelets could therefore be relevant cellular sources of IL-1 or extracellular ASC specks *in vivo* or could alter the inflammatory responses of other immune cells.

Here, we report that platelets are essential for the full inflammasome activation of innate immune cells. Co-culture with platelets not only boosted the NLRP3 activation and production of IL-1α, IL-1β, and IL-18 from human macrophages and neutrophils, but it was also crucial for the optimal production of IL-1 cytokines by human monocytes. Platelets specifically influenced the NLRP3 inflammasome activation of macrophages *in trans* by enhancing the transcription of NLRP3 and IL-1β. Using a series of complementary techniques that included assays with human platelets and megakaryocytes (MKs), as well as platelets and cells from knockout and transgenic mice, we demonstrated that platelets and MKs do not express the components of the canonical inflammasome (NLRP3, ASC, caspase-1, and IL-1β). Indeed, the effect of platelets on human monocyte-derived macrophages (hMDMs) was independent of IL-1 signaling and did not require direct cell contact, platelet-derived nucleic acids, lipid mediators, or purines, but it could be neutralized by heat inactivation. We further show that platelet depletion attenuated systemic production of IL-1β *in vivo*. Furthermore, platelet counts and plasma levels of IL-1β were positively correlated in naturally infected malaria patients. Moreover, we observed an enriched platelet signature among the highest-expressed genes in a cohort of pediatric patients with gain-of-function mutations in NLRP3 that cause Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID).

In summary, platelets fuel NLRP3 activity of immune cells and shape IL-1 inflammation. Thus, platelet-modifying therapies could have widespread implications for autoinflammatory and autoimmune diseases.

Results {#sec2}
=======

Platelets Boost IL-1 Production in Inflammasome-Activated Immune Cells {#sec2.1}
----------------------------------------------------------------------

The NLRP3 inflammasome is primarily assembled in myeloid cells. Although activated platelets are known to form aggregates with and modulate the functions of immune cells ([@bib3], [@bib19], [@bib28], [@bib55], [@bib79]), their effects on the inflammasome activation of leukocytes remains unexplored. To address this question, we investigated the influence of platelets on the production of IL-1 cytokines elicited by the bona fide NLRP3 inflammasome activators Nigericin and ATP in mouse and human immune cells. Mouse bone marrow-derived macrophages (BMDMs) ([Figure 1](#fig1){ref-type="fig"}A), hMDMs ([Figure 1](#fig1){ref-type="fig"}B), human neutrophils ([Figure 1](#fig1){ref-type="fig"}C), and human CD14^+^ monocytes ([Figure 1](#fig1){ref-type="fig"}D) were cultured or not with platelets. Co-cultures were left untreated or primed with lipopolysaccharide (LPS), followed by NLRP3 activation. The levels of IL-1β and tumor necrosis factor alpha (TNF-α) were measured in cell-free supernatants. A multiplex cytokine assay was used to additionally measure the production of IL-1α and IL-18, two other members of the IL-1 family, along with several other cytokines and growth factors in hMDMs and human neutrophils ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Co-culture with platelets boosted the production of IL-1β from mouse and human inflammasome-activated macrophages and human neutrophils ([Figures 1](#fig1){ref-type="fig"}A--1C) without significantly altering the release of lactate dehydrogenase (LDH) from activated cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Fitting a sigmoidal curve between the IL-1β levels produced in inflammasome-activated macrophages and the platelet-macrophage ratio, we found a strong (R = 0.8886, p = 0.0163) concentration-dependent effect of platelets in these cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C). The addition of platelets also boosted the release of IL-18 and IL-1α from activated hMDMs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Extending these results, the addition of platelets to neutrophils also enhanced their production of IL-8 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Platelets alone produced CCL5 (RANTES) and low levels of IL-18 that were close to the detection limit of the assays. Platelets lacked expression of most of the other investigated cytokines ([Figures 1](#fig1){ref-type="fig"}, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B), indicating that they do not directly contribute to the cytokines measured in the co-cultures. Notably, the co-culture of platelets with mouse macrophages, human monocytes, and neutrophils, but not hMDMs, resulted in diminished TNF-α production in response to LPS stimulation. These results suggest that despite NFκB being a common transcription factor regulating the production of TNF-α and IL-1 cytokines, platelets differentially regulate the production of these cytokines.Figure 1Platelets Boost Inflammasome Activation of Innate Immune Cells(A--D) IL-1β and TNF-α levels released by unstimulated (Unstim), LPS-primed, and Nigericin, or ATP-activated (A) WT BMDMs, (B) human macrophages (hMDMs), (C) neutrophils, or (D) monocytes. Cells were cultivated alone (−) or with platelets (+Plts) in the indicated ratios. Data is presented as floating bars (with mean and minimum to maximum values) and pooled from at least three independent experiments with cells and platelets from different donors. Each symbol represents the average from technical triplicates per blood donor or mouse.See also [STAR Methods](#sec4){ref-type="sec"} and [Figure S1](#mmc1){ref-type="supplementary-material"}.

Next, we asked whether platelets also influence the activity of other inflammasomes. For this, we activated AIM2 or NLRC4, respectively, by intracellular delivery of double-stranded DNA (dsDNA) (Poly\[dA:dT\]) ([Figure S1](#mmc1){ref-type="supplementary-material"}D) or the rod protein of the T3SS apparatus from *Salmonella typhimurium* (PrgI) ([STAR Methods](#sec4){ref-type="sec"}; [Figure S1](#mmc1){ref-type="supplementary-material"}E) in co-cultures of human platelets and macrophages. Stimulation of the AIM2 or NLRC4 inflammasomes in hMDMs resulted in IL-1β secretion, which was not significantly altered by the addition of platelets ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E), indicating that the platelet effect was NLRP3-specific. Co-culture with platelets also boosted IL-1β production from hMDMs primed with Toll-like receptor (TLR)2 or TLR7/8 agonists (Pam3Csk4 and R848, respectively) ([Figure S1](#mmc1){ref-type="supplementary-material"}F), indicating that the platelet effect is not exclusively mediated through TLR4. However, blockade of TLR4 signaling on hMDMs with resatorvid (TAK-242) ([@bib71]) partially prevented the effect of platelets ([Figure S1](#mmc1){ref-type="supplementary-material"}G), indicating that the platelet effect is in part orchestrated by TLR4. Together, these data show that platelets boost the production of IL-1 cytokines in NLRP3-activated innate immune cells.

Platelets Are Critical for the Inflammasome Activation of Human Monocytes {#sec2.2}
-------------------------------------------------------------------------

Notably, co-culture with platelets did not influence the production of IL-1β by inflammasome-activated monocytes ([Figure 1](#fig1){ref-type="fig"}D), likely due to the steady-state presence of contaminating platelets on the preparations of freshly isolated monocytes. To address that, we isolated CD14^+^ monocytes from peripheral blood using magnetic separation kits, added or not with a platelet removal cocktail ([STAR Methods](#sec4){ref-type="sec"}). Cell purity was assessed by fluorescence-activated cell sorting (FACS) ([Figure 2](#fig2){ref-type="fig"}A). Platelet depletion efficiently reduced the numbers of free platelets (CD41^+^CD14^--^) or platelets associated with monocytes (CD41^+^CD14^+^), while enriching the frequency of platelet-free monocytes (CD14^+^CD41^--^) ([Figures 2](#fig2){ref-type="fig"}A and 2B). Importantly, platelet depletion was not detrimental to monocytes, assessed by LDH release ([Figure S2](#mmc1){ref-type="supplementary-material"}B). However, platelet removal impaired the cytokine response of NLRP3-activated monocytes. Notably, monocyte responses could be restored by the re-addition of autologous platelets ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C). These data indicate that platelets are crucial for monocytes to trigger an optimal inflammatory response.Figure 2Platelets Are Critical for the Production of IL-1 Cytokines by Human Primary Monocytes(A) Representative FACS dot plots of CD41 and CD14 expression in human PBMCs, standard (Std-Mo), or platelet-depleted (PD-Mo) CD14^+^ monocytes (see [STAR Methods](#sec4){ref-type="sec"}).(B) Quantification of platelets (CD41^+^CD14^−^), platelet-monocyte aggregates (CD41^+^CD14^+^), and platelet-free monocytes (CD41^−^CD14^+^) in PBMCs and isolated monocytes.(C) IL-1β and TNF-α levels in cell-free supernatants of Std-Mo versus PD-Mo, or in platelet-depleted monocytes replenished with autologous platelets (PD-Mo + Plts, 50:1 Ptl:Cell), and stimulated as indicated.(D and E) IL-1β levels released by non-canonically activated Std-Mo, PD-Mo, or PD-Mo + Plts, stimulated with LPS (1 μg mL^−1^) for 16 h (D) or by inflammasome-activated THP-1 s ± platelets (E). Data is presented as floating bars (with mean and minimum to maximum values) and pooled from independent experiments. Each symbol represents the average from technical triplicates per blood donor. Data in (D) shows bar graph with Mean + SD, from a representative of two independent experiments.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Human monocytes can also engage an alternative inflammasome activation, in which LPS alone is sufficient to trigger IL-1β maturation and secretion ([@bib39]). To test the effect of platelet removal in alternatively activated monocytes, we stimulated standard or platelet-depleted CD14^+^ monocytes with LPS (1 μg mL^−1^) for 16 h. Similar to the effect on the canonical inflammasome ([Figure 2](#fig2){ref-type="fig"}C), platelet depletion impaired the IL-1β response from alternatively activated cells ([Figure 2](#fig2){ref-type="fig"}D), and the re-addition of platelets rescued their IL-1β production ([Figure 2](#fig2){ref-type="fig"}D).

Next, we asked whether co-culture with platelets could also enhance NLRP3 activation in the monocytic cell line THP-1, which has been used extensively to characterize the biology of the inflammasomes. As expected ([@bib39], [@bib40]), NLRP3-activated THP-1s were able to produce IL-1β on their own. Nevertheless, co-culture with platelets boosted the production of IL-1β by THP-1s to levels comparable to those produced by primary monocytes ([Figure 2](#fig2){ref-type="fig"}E). No IL-1β was detected on platelets cultivated alone. Together, these findings reveal that platelets are critical for optimal inflammasome activation by human monocytes.

Platelets Influence IL-1 Responses *In Vivo* {#sec2.3}
--------------------------------------------

As monocytes and macrophages are relevant sources of IL-1, we reasoned that platelets might influence IL-1 responses *in vivo*. Therefore, we investigated the effects of platelet depletion using a mouse model of systemic IL-1-dependent inflammation triggered by imidazoquinolinone compounds ([@bib51]). We induced thrombocytopenia in mice by intravenous (i.v.) injection of a GPIba monoclonal antibody (αCD42b). Treatment with αCD42b has been widely used in literature ([@bib9], [@bib12], [@bib94], [@bib106]) and results in a drop of the blood platelet counts ([Figures 3](#fig3){ref-type="fig"}A, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B), with no reported effects on the blood counts of other leukocytes ([@bib9], [@bib78]). As previously reported ([@bib51]), intraperitoneal (i.p.) injection of R848 in combination with LPS induced robust IL-1β systemically, measured in sera ([Figure 3](#fig3){ref-type="fig"}B), and locally, in peritoneal lavage (PEL) ([Figure 3](#fig3){ref-type="fig"}C). Notably, this response was attenuated by platelet depletion. Although levels of IL-1β were significantly lower in the sera of platelet-depleted mice ([Figure 3](#fig3){ref-type="fig"}B), we could not detect IL-1β in the PEL of all mice ([Figure 3](#fig3){ref-type="fig"}C). Importantly, platelet depletion did not affect the migration of neutrophils and monocytes to the peritoneum ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}B). These data suggest that the decrease in IL-1β levels was not due to reduced peritoneal leukocyte counts.Figure 3Platelets Influence IL-1 Levels *In Vivo*(A) Representative FACS plots and quantification of platelets in the blood of mice treated with a platelet-depleting Ab (αCD42b) or IgG control.(B and C) IL-1β levels in sera (B) or peritoneal lavage (C) from platelet-depleted mice after i.p. challenge with LPS + R848 (see [STAR Methods](#sec4){ref-type="sec"}).(D) FACS quantification of neutrophils and monocytes in peritoneal lavage of mice treated as in (C).(E) Correlation between plasma cytokines and blood cell counts or hemoglobin levels in naturally infected malaria patients (n = 78). Red lines, positive correlations; shaded areas, 95% confidence; squared symbols, outliers (see [STAR Methods](#sec4){ref-type="sec"}).(F) Volcano plot of log2 fold change versus significance (p value) highlighting the platelet-signature genes within transcripts of healthy (n = 14) versus pediatric patients (n = 22) with NLRP3 mutations (NLRP3mut) causing MWS/NOMID ([@bib8]).See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Platelets were reported to amplify IL-1 inflammation in rheumatoid arthritis (RA) ([@bib12]) and more recently in atherosclerosis ([@bib9]), two inflammatory diseases characterized by strong IL-1 inflammation ([@bib31], [@bib50], [@bib67], [@bib84]), supporting their role in modulating IL-1 levels *in vivo*. In line with this hypothesis, a positive correlation between blood platelet counts and plasma IL-1β concentrations was recently reported in a cohort of 500 healthy, Caucasian volunteers ([@bib75], [@bib99]). However, blood leukocyte counts were equally correlated with plasma levels of IL-1β in that study, hindering the precise contribution of platelets for the IL-1β concentrations ([@bib99]). To investigate the relation between platelet counts and IL-1β concentrations in the context of disease, we studied a cohort of human subjects naturally infected with *Plasmodium vivax*, the predominant cause of malaria in the Brazilian Amazon ([@bib47]). Infections with *P. vivax* commonly cause pro-inflammatory cytokine imbalance ([@bib5]), with thrombocytopenia and anemia being the two most commonly associated complications. We found that platelet counts positively correlated with plasma IL-1β concentrations (Spearman**'**s R = 0.504, p = 0.0028). Despite a positive trend, no correlations were found between platelet counts and IL-1α (R = 0.15, p = 0.37) or TNF-α (R = 0.014, p = 0.917) ([Figure 3](#fig3){ref-type="fig"}E). Unexpectedly, IL-18 levels were negatively correlated with platelet counts (R = −0.45, p \< 0.0001), which suggests that different mechanisms regulate the production of this cytokine *in vivo*. Supporting this hypothesis, heme ([@bib62]) and oxidized hemoglobin were shown to activate the NLRP3 inflammasome ([@bib77]). Indeed, IL-18 (R = −0.32, p = 0.005) and TNF-α (R = −0.29, p = 0.003) correlated with hemoglobin levels ([Figure 3](#fig3){ref-type="fig"}E), suggesting that anemia may be a contributing factor for the regulation of these cytokines, but not for the associations between platelet counts and IL-1β. Importantly, none of the cytokines investigated correlated with leukocyte counts ([Figure 3](#fig3){ref-type="fig"}E) in the malaria cohort. As leukocytes are a relevant source in IL-1 cytokines in the blood, these data support that platelets are major contributors in the regulation of IL-1 levels in this context. IL-1β levels also had no correlation with parasitemia (data not shown), suggesting that IL-1β production may not be caused by *Plasmodium-*associated danger molecules ([@bib35]).

Next, we asked whether there is a relationship between platelets and inflammation in exclusively IL-1β-driven human autoinflammatory syndromes ([@bib14]). We generated a platelet gene signature comprising 45 transcripts known to be either platelet-specific or strongly associated with platelet activity from direct comparisons of publicly available gene expression analyses of purified human platelets ([@bib37], [@bib87]). Remarkably, 42 out of 45 platelet-signature genes were upregulated in the whole blood of pediatric patients harboring *NLRP3* mutations (*NLPR3mut*) associated with the IL-1-driven autoinflammatory disorders MWS and NOMID ([@bib8], [@bib42]), compared to healthy children ([Figure 3](#fig3){ref-type="fig"}F). Importantly, as reported in the original cohort ([@bib42]), the baseline clinical manifestations and blood cell counts of MWS/NOMID patients were within the pediatric reference ranges, supporting that differences in blood cell counts are likely not responsible for the changes we observed. Collectively, these findings support that platelets influence IL-1β *in vivo*.

Platelet Effect on Immune Cells Is Independent of Platelet-Derived IL-1 or Platelet Inflammasomes {#sec2.4}
-------------------------------------------------------------------------------------------------

Previous reports have indicated that platelets express IL-1 cytokines, including IL-1α ([@bib97]), IL-1β ([@bib29]), and IL-18 ([@bib2]). However, as shown in [Figures 1](#fig1){ref-type="fig"}, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B, IL-1α and IL-1β were not detected in monocultures of platelets in our experimental settings. To exclude the possibility that platelets directly contribute to the IL-1 cytokines measured in our assays, we performed co-culture experiments using platelets or BMDMs from mice with targeted genetic deficiency in IL-1 proteins or IL-1 receptors. First, we activated the NLRP3 inflammasome in wild-type (WT) BMDMs co-cultured with platelets from either WT or IL-1β-deficient (*Il1b*^--/--^) mice. We found that *Il1b*^--/--^ platelets were equally able to boost IL-1β production in inflammasome-activated BMDMs as WT platelets ([Figure 4](#fig4){ref-type="fig"}A). Similarly, the addition of WT platelets to BMDMs from IL-1R-deficient mice (*Il1r*^--/--^) also boosted their IL-1β production upon inflammasome activation ([Figure 4](#fig4){ref-type="fig"}B), thus excluding a role for platelet-derived IL-1α in mediating the response. Finally, the addition of platelets to *Il-18r*^--/--^ BMDMs equally boosted their IL-1β production toward LPS + Nigericin ([Figure 4](#fig4){ref-type="fig"}C), indicating that neither the platelet-derived IL-1α/β nor the IL-18 cytokines could be responsible for the platelet effect.Figure 4The Effect Is Independent of Platelet-Derived IL-1 Cytokines or Inflammasomes(A) IL-1β released by WT BMDMs ± platelets (5:1 ratio) from WT or *Il1b*^--/--^ mice. Bar graph with Mean and SD from one experiment with three mice.(B and C) IL-1β levels in cell-free supernatants of WT or *Il1r*^--/--^ (B) or *Il18r*^--/--^ (C) BMDMs ± platelets (5:1 ratio) from WT mice.(D) IL-1β levels in cell-free supernatants of WT, *Nlrp3*^--/--^, or Pycard^--/--^ BMDMs ± WT platelets (5:1 ratio). Confocal imaging of hMDMs co-cultured with platelets (50:1 ratio). Cells were pretreated or not with Cytochalasin D before the addition of platelets. Blue (Draq5, nuclei); red (wheat germ agglutinin \[WGA\], plasma membrane); green (anti-CD41, platelets).(E) IL-1β released by hMDMs treated as in (D).(F) Schematics of *trans*-well and IL-1β released by hMDMs cultured alone, in direct co-cultures with platelets (Well), or in *trans*-well (insert).(G and H) IL-1β released by hMDMs ± platelets or platelet (G) and MK (H) supernatants. Graphs show floating bars (with mean and minimum to maximum values) from pooled data from two to four independent experiments. Each symbol represents the average of technical triplicates from different donors.

Recent studies reported the assembly of the NLRP3 inflammasome in platelets and their involvement in the pathogenesis of dengue ([@bib46]) and sickle cell disease ([@bib103]). To determine whether the co-activation of platelet NLRP3 could contribute to the IL-1 production in co-cultures, we tested if the addition of WT platelets could compensate for the impaired IL-1 response of *Nlrp3*^--/--^ or *Pycard*^--/--^ (*Asc*^--/--^) BMDMs. We stimulated LPS-primed *Nlrp3*^--/--^ or *Pycard*^--/--^ BMDMs with Nigericin or ATP, alone or in co-culture with WT platelets. As expected, macrophages from *Nlrp3*^--/--^ and *Pycard*^--/--^ mice failed to produce IL-1β in response to inflammasome activation ([Figure S2](#mmc1){ref-type="supplementary-material"}D). The addition of WT platelets to *Nlrp3*^--/--^ or *Pycard*^--/--^ macrophages had no effect on the IL-1β production by these BMDMs ([Figure S2](#mmc1){ref-type="supplementary-material"}D), indicating that the activation of inflammasomes in platelets is not involved in the amplification of macrophage IL-1β responses. To determine whether the NLRP3/ASC inflammasome is expressed and assembled in platelets, we imaged inflammasome assembly in bone marrow (BM) cells from transgenic (Tg) ASC-mCitrine mice ([@bib100]). ASC-mCitrine^+^ BM cells were stained for leukocytes (CD45), neutrophils (Ly6G), and platelets (CD41) and assessed by flow cytometry and confocal microscopy. While ASC was clearly visualized and assembled into fluorescent specks in inflammasome-activated leukocytes (CD45^+^), macrophages (CD45^+^F4/80^+^), and neutrophils (CD45^+^Ly6G^+^), it was not observed in platelets and MKs (CD41^+^cells) ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). These results were confirmed using flow cytometry and confocal imaging of BM cells from ASC-mCherry knock-in reporter mice ([Figure S3](#mmc1){ref-type="supplementary-material"}E).

Most studies reporting the presence ([@bib15], [@bib29]) or activity ([@bib44], [@bib52]) of IL-1 cytokines or inflammasome molecules used preparations of washed platelets without assessment of purity, which could not rule out the presence of contaminating leukocytes in their platelet preparations ([@bib80]). We therefore re-evaluated the expression of the canonical inflammasome components in platelets and peripheral blood mononuclear cells (PBMCs) from healthy volunteers. The purity of platelet preparations was assessed by flow cytometry, microscopy, and qPCR using platelet (PF4) and leukocyte markers (*CD45*, *CD14*) ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4E and [Table S1](#mmc1){ref-type="supplementary-material"}). Importantly, both freshly isolated human and mouse platelets remained viable after purification and upregulated P-selectin (CD62P) upon thrombin stimulation ([Figures S3](#mmc1){ref-type="supplementary-material"}F and [S4](#mmc1){ref-type="supplementary-material"}E). Nevertheless, human platelets did not express the inflammasome components NLRP3, ASC, and caspase-1, nor IL-1β at the mRNA ([Figure S4](#mmc1){ref-type="supplementary-material"}D) and protein level ([Figures S4](#mmc1){ref-type="supplementary-material"}F--S4H), although these molecules were promptly detected in PBMCs from the same donors and increased upon LPS stimulation. Furthermore, unlike the human monocytic line THP-1, no expression of IL-1β and inflammasome molecules was detected in the human megakaryocytic cell MEG-01 ([Figure S3](#mmc1){ref-type="supplementary-material"}G), which also failed to secrete mature IL-1β upon inflammasome activation ([Figure S3](#mmc1){ref-type="supplementary-material"}H).

Finally, we re-analyzed publicly available transcription profiles of purified platelets from five independent studies ([@bib30], [@bib41], [@bib65], [@bib83], [@bib93]), including the gene expression profiles of platelets from patients with dengue ([@bib30]) and sickle cell disease ([@bib83]; [Figures S5](#mmc1){ref-type="supplementary-material"}A--S5E). In all these studies, we re-assessed the expression of IL-1β and the inflammasome components NLRP3, ASC, and caspase-1 using the expression of platelet markers PF4 (CXCL4) or platelet-derived growth factor A (PDGFA) as comparisons ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5E). None of the NLRP3, ASC, caspase-1, or IL-1β transcripts were detected in human platelets in these studies ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5E). Together with our previous findings, these observations support the conclusion that human and mouse platelets do not express the components of the canonical NLRP3 inflammasome and are therefore unable to assemble inflammasomes.

The Platelet Effect Is Mediated by a Soluble and Constitutive Factor {#sec2.5}
--------------------------------------------------------------------

Phagocytosis of activated platelets has been shown to regulate platelet and neutrophil function, survival, and differentiation ([@bib7], [@bib21], [@bib57], [@bib90]). To determine whether phagocytosis is responsible for the effect of platelets on inflammasome activation, we performed confocal imaging of hMDMs ([Figure 4](#fig4){ref-type="fig"}D) and purified blood neutrophils ([Figure S2](#mmc1){ref-type="supplementary-material"}E) incubated with freshly isolated platelets. Co-cultures were stimulated with LPS, followed by inflammasome activation. Both hMDMs ([Figure 4](#fig4){ref-type="fig"}D) and neutrophils ([Figure S2](#mmc1){ref-type="supplementary-material"}E) phagocytosed platelets; however, pretreatment of hMDMs with the phagocytosis inhibitor Cytochalasin D did not prevent the platelet-mediated boost of IL-1β ([Figure 4](#fig4){ref-type="fig"}E). Furthermore, platelets were able to boost the IL-1β responses of hMDMs in both direct and in *trans*-well co-cultures ([Figure 4](#fig4){ref-type="fig"}F), and cell-free supernatant from resting, LPS-stimulated, or thrombin-activated platelets also enhanced IL-1β production from hMDMs ([Figure 4](#fig4){ref-type="fig"}G). Importantly, thrombin had no effect on macrophages stimulated in the absence of platelets ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Thus, the platelet influence on IL-1β production by inflammasome-activated macrophages is independent of cell contact. In contrast, the transfer of platelet supernatants to cultures of human neutrophils or monocytes did not promote a significant increase in the production of IL-1β ([Figure S2](#mmc1){ref-type="supplementary-material"}G; data not shown), suggesting that cell-to-cell contact may be required for the platelet-boosting effects in these cells.

We observed that supernatants from quiescent and activated platelets had similar effects on the inflammasome activation of hMDMs ([Figure 4](#fig4){ref-type="fig"}G). To determine whether this capacity of quiescent platelets was due to undetectable activation during isolation, we transferred supernatants from resting MEG-01 to cultures of hMDMs. Similar to platelets, supernatants from resting MEG-01 boosted the inflammasome activity in hMDMs ([Figure 4](#fig4){ref-type="fig"}H). This finding points toward the presence of a soluble and constitutively expressed factor secreted by both platelets and MKs, which modulates the inflammasome activity of macrophages.

Platelets License NLRP3 Transcription to Boost Inflammasome Activation on Human Macrophages {#sec2.6}
-------------------------------------------------------------------------------------------

In most immune cells, the activation of NLRP3 requires a priming stimulus, such as the engagement of pattern recognition receptors, that initiates the transcription of *NLRP3*. The amount of NLRP3 available in the cytosol is a key limiting factor regulating its activation. Since we observed that the platelet effect was specific to the activation of the NLRP3 inflammasome ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E), we investigated if the platelet effect on macrophages occurs at the transcriptional level during priming or afterward during activation of the NLRP3 inflammasome. To this end, we co-cultured NLRP3-overexpressing immortalized mouse macrophages (NLRP3FiMøs) with platelets and directly stimulated these cells with Nigericin. As the LPS priming signal is also required for the upregulation of pro-IL-1β, we assessed caspase-1 activity using a specific caspase-1 luminescence assay as a readout. The addition of platelets to NLRP3FiMøs did not enhance their caspase-1 activity ([Figure 5](#fig5){ref-type="fig"}A), supporting that platelets influence the inflammasome activation of hMDMs by enhancing the transcription of NLRP3. To determine whether platelets modulate the expression of other inflammasome molecules, we evaluated hMDMs cultivated or not with platelet supernatants, which were used to minimize the detection of transcripts arising from platelets. The addition of supernatants from resting platelets to macrophages boosted their expression of IL-1β ([Figure 5](#fig5){ref-type="fig"}B and [Table S1](#mmc1){ref-type="supplementary-material"}). Surprisingly, the platelet supernatant was as effective as LPS to induce the expression of NLRP3 and pro-IL-1β protein ([Figure S2](#mmc1){ref-type="supplementary-material"}H, lanes 1 and 3). However, the platelet supernatant did not alter the expression of pro-caspase-1 or ASC ([Figure 5](#fig5){ref-type="fig"}B). In conformity with increased NLRP3 availability in the cytosol, exposure to platelets boosted the formation of ASC specks in hMDMs ([Figure 5](#fig5){ref-type="fig"}C). Importantly, cells stained with isotype-matched immunoglobulin G (IgG), as well as platelets cultured alone, did not show ASC specks ([Figures 5](#fig5){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}A). Co-culture with platelets or exposure to their supernatants increased caspase-1 activation and maturation of IL-1β in supernatants of hMDMs ([Figures 5](#fig5){ref-type="fig"}D--5F). Again, these proteins were not present in platelets ([Figures 5](#fig5){ref-type="fig"}D and 5E; Plts alone). We also detected pro-IL-1β in cell-free supernatants of LPS-primed hMDMs, likely due to cell death during LPS priming. Furthermore, despite lacking pro-IL-1β mRNA ([Figure S4](#mmc1){ref-type="supplementary-material"}D) and protein ([Figures 5](#fig5){ref-type="fig"}D, lane 11, and [S4](#mmc1){ref-type="supplementary-material"}G), platelets and their supernatants increased the concentrations of pro-IL-1β even on unstimulated hMDMs ([Figure 5](#fig5){ref-type="fig"}D, lanes 3 and 4). Contrary to NLRP3, which requires priming for its transcription, NLRC4 and AIM2 are constitutively expressed in the cytosol of hMDMs, which might explain why platelets had minor effects on the AIM2- or NLRC4-dependent IL-1β secretion ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). Altogether, these findings indicate that platelets boost inflammasome activation by enhancing the transcription of pro-IL-1β and NLRP3 in hMDMs.Figure 5Platelets Enhance NLRP3 and Pro-IL-1 Transcription in Human Macrophages(A) Caspase-1 activity in cell-free supernatants of NLRP3-overexpressing mouse macrophages ± platelets (50:1 ratio). Cells were left resting (Unstim) or activated with Nigericin (10 μM, 90 min) without LPS priming.(B) qPCR analysis of the indicated genes in hMDMs ± platelet supernatants.(C) Confocal imaging and quantification of ASC specks in LPS-primed and Nigericin-activated hMDMs ± platelets (50:1 ratio). Scale bar, 11 μm.(D and E) Immunoblotting for IL-1β (D) or caspase-1 (E) in cell-free supernatants, as well as β-actin in cell lysates of resting, LPS-primed hMDMs ± platelets (50:1 ratio), or platelet supernatants. Different donors are indicated.(F) Caspase-1 activity in cell-free supernatants of hMDMs treated as in (C). Graphs show floating bars (with mean and minimum to maximum values) from pooled data from three or four independent experiments. Each symbol represents the average of technical triplicates from different donors.

The Platelet-Mediated Amplification of Inflammasome Activity Requires Calcium and Can Be Prevented by Heat Inactivation {#sec2.7}
-----------------------------------------------------------------------------------------------------------------------

Platelets are sources of lipid mediators ([@bib45]) such as prostaglandins (COX-1/2-derived mediators), which regulate LPS-induced pro-IL-1β transcription ([@bib109]) and inhibit TNF-α in macrophages ([@bib20], [@bib106], [@bib109]). We therefore inhibited COX-1/2 by pre-treating platelets with aspirin ([@bib106]). Aspirin had no effect on platelet ability to boost IL-1β production in hMDMs ([Figure 6](#fig6){ref-type="fig"}A). Similarly, pre-treatment of platelets with Zileuton (Zt), an inhibitor of leukotriene synthesis, did not block the platelet effect. Of note, aspirin and Zt had no effect on IL-1β production when used directly on hMDMs ([Figure 6](#fig6){ref-type="fig"}A).Figure 6A Platelet-Derived Ca^2+^-Dependent Protein Boosts NLRP3 Activity in Human Macrophages(A) IL-1β released by resting (Unstim), LPS-primed, and Nigericin-activated hMDMs ± aspirin or Zileuton (Zt) pre-treated platelets (50:1 ratio)(B and C) IL-1β levels released by unstimulated or LPS-primed hMDMs ± platelets. Cells were incubated with Benzonase (B) or Apyrase (C) before LPS priming and inflammasome activation.(D) IL-1β levels in co-cultures of platelets and hMDMs added with the indicated concentrations of ADP or equivalent dilutions in water.(E and F) IL-1β released by hMDMs stimulated as in (A) and co-cultured with heat-inactivated (HI), fixed platelets, or fresch or HI platelet supernatants.(G) IL-1β released by hMDMs activated as in (A) and added with the indicated recombinant proteins.(H and I) IL-1β levels in co-cultures of platelets and hMDMs added with BAPTA in Ca^2+^-free medium (H) or BAPTA AM (I) in normal RPMI medium before activation.(J) IL-1β levels released by inflammasome-activated hMDMs incubated with the indicated concentrations of calcium chloride (CaCl~2~) in Ca^2+^-free medium. Graphs show floating bars (with mean and minimum to maximum values) from pooled data from two to four independent experiments. Each symbol represents the average of technical triplicates from different donors.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Activated platelets can also release nucleic acids and nucleosides that display inflammatory properties ([@bib82]). However, degradation of free nucleic acids by Benzonase (Bz) did not prevent the effect of platelet co-culture on IL-1β production ([Figure 6](#fig6){ref-type="fig"}B). As platelets store other purines including ADP and ATP, we added apyrase (Apy) to the co-culture of hMDMs with platelets. Apyrase did not alter the effect of platelets on the inflammasome activity of hMDMs ([Figure 6](#fig6){ref-type="fig"}C). Likewise, the direct addition of extracellular ADP to inflammasome-activated hMDMs also failed to recapitulate the platelet effect ([Figure 6](#fig6){ref-type="fig"}D). This is in line with our findings that platelets boost macrophage IL-1β production through transcriptional regulation during the priming phase of inflammasome activation ([Figures 5](#fig5){ref-type="fig"}A and 5B). Altogether, our findings suggest that the platelet-derived factor responsible for the inflammasome boosting does not belong to the classes of nucleic acids, purines, or derivatives of arachidonic acid.

Therefore, we speculated whether the platelet-derived factor could be a protein. Ratifying this hypothesis, both heat inactivation and fixation of platelets ([Figure 6](#fig6){ref-type="fig"}E) or platelet supernatants ([Figure 6](#fig6){ref-type="fig"}F) extinguished their effects on inflammasome activation in hMDMs. Multiple cytokines were detectable in supernatants of resting and activated platelets in our assays ([Figure S1](#mmc1){ref-type="supplementary-material"}A), including CCL5 (RANTES), CXCL12 (SDF1α), IL-18, and PDGF-BB. Additional literature reported that platelets are cellular sources of CD40L, PF4, brain-derived neurotrophic factor (BDNF), P-selectin, and CXCL7 ([@bib55], [@bib89]). After the direct addition of human recombinant proteins to hMDMs ([Figures 6](#fig6){ref-type="fig"}G, [S6](#mmc1){ref-type="supplementary-material"}B, and S6C), inhibitors or blocking antibodies against platelet-derived cytokines ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E), or co-cultures involving cells from animals deficient for chemokine receptors ([Figure S6](#mmc1){ref-type="supplementary-material"}F), we excluded a role for CXCL1, CCL5, CXCL12, CXCL7, PDGF-BB, epidermal growth factor (EGF), vascular endothelial growth factor (VEGFA), CD40L, PF4, BDNF, and P-selectin as contributors to the platelet effect.

The failure of the above-mentioned α-granule-derived proteins to boost IL-1β production in hMDMs suggested that molecules contained in the dense granules of platelets could mediate the IL-1β boosting in activated hMDMs. Platelet-dense granules are rich stores of serotonin (5-HT) and Ca^2+^. However, we found that neither the addition of 5-HT ([Figure S6](#mmc1){ref-type="supplementary-material"}G) nor the blockade of its uptake by hMDMs with fluoxetine ([@bib36], [@bib68]) altered IL-1β production by inflammasome-activated hMDMs ([Figure S6](#mmc1){ref-type="supplementary-material"}H).

We next examined the effect of chelating extracellular or intracellular Ca^2+^ with 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) and BAPTA-AM, respectively. Notably, treatment of co-cultures with BAPTA, but not with the membrane-permeable BAPTA-AM, prevented the platelet effect without interfering with the basal response of hMDMs ([Figures 6](#fig6){ref-type="fig"}H and 6I). However, the addition of calcium chloride (CaCl~2~) to inflammasome-activated hMDMs did not evoke additional IL-1β secretion ([Figure S6](#mmc1){ref-type="supplementary-material"}I), suggesting that Ca^2+^ is required but not sufficient for the platelet effect.

Cells sense extracellular Ca^2+^ primarily through calcium sensing receptors (CaSR), which are G-protein-coupled receptors (GPCRs). To test the role of CaSR, we pre-treated hMDMs with the CaSR-selective inhibitor NPS2143. We found that NPS2143 blocked the platelet effect on hMDMs ([Figure 6](#fig6){ref-type="fig"}J). Of note, recapitulating the platelet effect, allosteric activation of CaSR with the calcimimetic compound R568 boosted the IL-1β response of inflammasome-activated hMDMs ([Figure 6](#fig6){ref-type="fig"}K). These findings indicate that a heat-sensitive protein that induces calcium signaling via CaSR is involved in the platelet-mediated increase of IL-1β from inflammasome-activated hMDMs.

A Combination of Platelet-Derived Proteins Might Boost Inflammasome Activation of Macrophages {#sec2.8}
---------------------------------------------------------------------------------------------

Next, we assessed the protein secretome of platelets and MKs and identified additional candidates similarly secreted by these cells that could mediate the IL-1 boosting effect ([Figures 7](#fig7){ref-type="fig"}A, 7B, [S7](#mmc1){ref-type="supplementary-material"}A, and S7B). Supernatants from quiescent or LPS-treated human platelets ([Figure 7](#fig7){ref-type="fig"}A; n = 4), as well as from MEG-01 cells ([Figure 7](#fig7){ref-type="fig"}B, n = 3) were evaluated by liquid chromatography-tandem mass spectrometry (LC-MS). As our findings in [Figures 4](#fig4){ref-type="fig"}G and 4H indicated the presence of a factor ubiquitously present in the supernatants of resting and activated platelets, we directed further analysis to proteins that remained unchanged (fold change \> −1.5 and \< 1.5) following LPS stimulation in both cell types. Among the proteins similarly secreted by platelet and MKs, we identified members of the TGF-β and S100 family and thrombospondin-1 (THBS1), which figured as the most abundant protein in platelet supernatants ([Figures 7](#fig7){ref-type="fig"}A and 7B). Notably, TGF-β, S100, and THBS1 require Ca^2+^ for their activity ([@bib11], [@bib18], [@bib74]). Additionally, in line with our findings that TLR4 signaling is partially involved in the platelet effect ([Figure S1](#mmc1){ref-type="supplementary-material"}G), THBS1 can activate TLR4 ([@bib61]), can regulate IL-1β in macrophages ([@bib95]), and is necessary for the full activity of TGF-β ([@bib26]). We therefore tested the effect of these proteins on the platelet-mediated boosting of inflammasomes. We tested the addition of recombinant human TGF-β (rhTGF-b1) to inflammasome-activated hMDMs. Consistent with previous reports of an antagonistic effect of TGF-β on TNF-α signaling ([@bib101], [@bib102], [@bib107]), the addition of rhTGF-b1 to hMDMs inhibited their production of TNF-α triggered by LPS ([Figure S7](#mmc1){ref-type="supplementary-material"}C). However, rhTGF-b1 did not influence the IL-1β response ([Figure 7](#fig7){ref-type="fig"}C). Likewise, selective inhibition of the TGF-β receptor by pre-treating hMDMs with SB431542 ([@bib72]) did not prevent the platelet effect ([Figure 7](#fig7){ref-type="fig"}D), despite preventing the downregulation of TNF-α ([Figure S7](#mmc1){ref-type="supplementary-material"}C). These data indicate that TGF-β is likely not the platelet-derived factor enhancing the NLRP3 activity of hMDMs, but it might underlie the regulation of TNF-α.Figure 7Platelets Have Broad Effects on Macrophages That May Contribute to Boosting of Inflammasome Activation(A and B) Proteomics of cell-free supernatants from resting (Unstim) or LPS-treated (A) human platelets (n = 4) or MK (B) (n = 3). Darker points show proteins with log2 fold ≥ 2 between LPS and Unstim.(C--G) IL-1β released by resting or inflammasome-activated hMDMs added with (C) rhTGF-β1 or (D) pre-treated with SB-431542, (E) added with rhS100A8/9, (F) pre-treated with TAK242 (0.5 μg mL^−1^) and an αRAGE mAb (10 μg mL^−1^), or (G) added with rhTHBS1.(H) IL-1β released by inflammasome-activated BMDMs cultured with WT or *Thbs1*^−/−^ platelet supernatants.(I) IL-1β and TNF-α levels released by R848-primed and Nigericin-activated hMDMs ± platelets. hMDMs were pre-treated with the CD36 inhibitor SSO. Graphs show floating bars (with mean and minimum to maximum values) from pooled data from two to four independent experimentsSee also [Figure S7](#mmc1){ref-type="supplementary-material"}.

S100 proteins are important regulators of Ca^2+^ homeostasis, and platelet-derived S100A8/9 has been shown to induce inflammation ([@bib66], [@bib104]). S100A8/9 is enriched in platelets and binds to membrane receptors such as TLR4, receptor for advanced glycation endproducts (RAGE), and CD36 ([@bib11]). TLR4 and CD36 are also known receptors for THBS1 ([@bib61], [@bib95]). However, we found that addition of neither rhTHBS1 ([Figures 7](#fig7){ref-type="fig"}G and [S7](#mmc1){ref-type="supplementary-material"}E) nor rhS100A8/9 ([Figure 7](#fig7){ref-type="fig"}E) to hMDMs influenced their basal response to LPS + Nigericin. Of note, rhS100A8/9 induced TNF-α secretion from hMDMs ([Figure S7](#mmc1){ref-type="supplementary-material"}D). Furthermore, supernatants from *Thbs1*^−/−^ platelets were as efficient as WT platelets in boosting IL-1β release and caspase-1 activity from inflammasome-activated BMDMs ([Figure 7](#fig7){ref-type="fig"}H), and RAGE inhibition antibodies had no effect on the platelet boosting of IL-1β ([Figures 7](#fig7){ref-type="fig"}F and [S7](#mmc1){ref-type="supplementary-material"}G). These findings led us to conclude that platelet-derived THBS1 and S100A8/A9 are not, individually, responsible for the platelet effect on macrophages.

As THBS1 and S100 proteins bind to CD36, we tested the effect of CD36 inhibition with Sulfosuccinimidyl oleate (SSO) ([@bib56]). SSO interfered with IL-1β and TNF-α release ([Figure 7](#fig7){ref-type="fig"}I) and caspase-1 activity ([Figure S7](#mmc1){ref-type="supplementary-material"}F) in both the presence and absence of platelets. Nevertheless, even in the presence of SSO, platelets increased both the release of IL-1β and the activity of caspase-1 from macrophages compared to SSO-pre-treated macrophages in monoculture.

As single inhibition of TLR4, RAGE, and CD36 did not completely abrogate the platelet effect, we speculated that a combined activity of platelet-derived S100 and THBS1 could mediate the boosting of IL-1β on hMDMs. An experimental strategy to block TLR4/RAGE and CD36 resulted in complete inhibition of IL-1β, TNF-α, and caspase-1 activity of hMDMs ([Figure S7](#mmc1){ref-type="supplementary-material"}G), thus precluding us to conclude whether these proteins are synergistically involved in the platelet-mediated enhancement of IL-1β response of hMDMs. Hence, additional work is required to delineate the mechanisms by which platelets affect the inflammasome activation of hMDMs.

Discussion {#sec3}
==========

Here, we report that the interaction with platelets licenses NLRP3, potentiates inflammasome activation and production of IL-1 cytokines by innate immune cells, and is critical for NLRP3-activation in human monocytes. The platelet effect is mediated by a yet unidentified soluble factor (or factors), which enhances NLRP3 transcription and boosts inflammasome activation. Hence, our work identifies platelets as additional players in governing the production of IL-1 cytokines and emphasizes that full inflammasome activity *in vivo* is too complex to be modeled by *in vitro* monocultures of single-cell populations.

Platelets are key players in inflammation ([@bib19], [@bib28], [@bib55], [@bib79]) and express TLRs that sense infection and initiate inflammatory responses ([@bib4]). While platelets are known to react to LPS ([@bib23], [@bib4]), they do not constitutively express membrane CD14 ([@bib27]) and require soluble CD14 from plasma for TLR4 signaling ([@bib111], [@bib27]).

Our work adds to a growing bulk of evidence that platelet parameters, such as their blood counts, can be additional causes of variation in the concentrations of circulating cytokines ([@bib48], [@bib88], [@bib99]). Platelets secrete a large array of proteins ([@bib24], [@bib73]), which affect leukocytes in different ways ([@bib55], [@bib94]). They have also been proposed as sources of IL-1 cytokines and, more recently, to assemble inflammasomes ([@bib25], [@bib46], [@bib103]).

Our work challenges these findings with a series of complementary techniques that demonstrate that platelets lack expression of NLRP3, ASC, and caspase-1 and are therefore incapable of assembling inflammasomes. Those included experiments using platelets and BMDMs from mice lacking IL-1 proteins or their receptors ([Figures 4](#fig4){ref-type="fig"}A--4C); mice lacking inflammasome molecules ([Figure S2](#mmc1){ref-type="supplementary-material"}D), megakaryocytes, and platelets from humans ([Figures S3](#mmc1){ref-type="supplementary-material"}F, S3G, and [S4](#mmc1){ref-type="supplementary-material"}); and transgenic or knockin inflammasome reporter mice ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E), as well as a MS-based proteomics analysis of supernatants from human platelets and MK cell line ([Figures 7](#fig7){ref-type="fig"} and [S7](#mmc1){ref-type="supplementary-material"}). Our conclusions were further supported by a meta-analysis of transcriptomics from five independent studies with human platelets ([Figure S5](#mmc1){ref-type="supplementary-material"}). We believe that the discrepancies are likely because the studies reporting inflammasomes on platelets relied on fluorescence assessment of inflammasome components, using antibodies of weak specificity ([@bib10]), and without quantitative measurement of proteins in platelet lysates by immunoblotting. Likewise, IL-1 expression on platelets is reported with conflicting results in literature. Some studies describe expression of IL-1 in activated platelets ([@bib29], [@bib63], [@bib97]), while others find IL-1 activity in bioassays ([@bib44], [@bib52]), with no evidence of the cytokine itself. Notably, throughout all our experiments, we assessed the purity (leukocyte contamination CD14 and/or CD45; [Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E, [S4](#mmc1){ref-type="supplementary-material"}D, and S4F) as well as activation capacity (ability to upregulate CD62p upon thrombin stimulation; [Figures S3](#mmc1){ref-type="supplementary-material"}F and [S4](#mmc1){ref-type="supplementary-material"}E) of our platelet preparations. These important controls were not performed in the aforementioned studies. Hence, it cannot be ruled out that their platelet preparations are free of contaminating leukocytes ([@bib80]). For example, a preparation of 5 × 10^8^ platelets, commonly used in previous studies for RNA isolation, with a 98% purity (assessed by FACS) could easily contain ∼2 × 10^6^ contaminating leukocytes, which could account for a significant portion of RNA within a sample. Supporting this, IL-1β expression on platelet preparation is closely correlated to the presence of contaminating leukocytes ([@bib80]).

In line with our findings, platelets have been reported to amplify IL-1β-mediated inflammation in RA ([@bib12]), an IL-1-driven disease ([@bib32]), and a recent study demonstrated pro-atherogenic effects of platelets by and skewing monocytes into a pro-inflammatory macrophage phenotype ([@bib9]). Platelet depletion in mice with RA ([@bib12]) or in *Ldlr*^--/--^ mice fed a western diet ([@bib9]) attenuated inflammation and improved clinical outcomes. However, it was not possible in these studies to distinguish whether these effects were caused by decreased platelet-derived cytokines or by the influence of platelets on other immune cells, as we report here.

Our data confirm their relevance to human physiology and disease, as high blood platelet counts are found in patients ([@bib22]) and mouse models of IL-1-driven auto-inflammatory disorders ([@bib13]). In Kawasaki disease (KD), an acute systemic vasculitis in children for which thrombocytosis is a common feature, human and experimental mouse models have determined a critical role of IL-1β in the cardiovascular pathogenesis. Furthermore, thrombocytosis and platelet activation are predictive of the development of coronary aneurysm in KD ([@bib16], [@bib60]).

As both IL-1α and IL-1β induce thrombocytosis in mice ([@bib54], [@bib76], [@bib98]), platelets could help feed an inflammatory loop by potentiating IL-1 signaling, which in turn triggers platelet biogenesis. However, whether thrombocytosis is a marker of disease or a contributor to pathogenesis remains to be investigated. Platelet counts have been correlated with the concentrations of other cytokines that affect platelet production in immune thrombocytopenia (ITP) and other diseases. Those include CD40L, CXCL5, CCL5, EGF, VEGF, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)γ, monocyte chemoattractant protein 1 (MCP-1), IL-8, and PDGF-BB ([@bib38], [@bib81]). Thus, the contribution of platelets to cytokine production in human biology warrants further investigation.

Notably, co-culture with platelets impaired the LPS-induced TNF-α production in several immune cells. This observation is in line with previous studies ([@bib6], [@bib43], [@bib106]) and may be explained by the reported ability of platelets to sequester TNF-α and IL-6 released from LPS-stimulated monocytes ([@bib19]). Platelets have a protective role in sepsis through the regulation of TNF-α and IL-6 via the secretion of a COX1/PGE2/EP4-dependent lipid mediator ([@bib106]). In line with these findings, we observed that TNF-α is regulated via a platelet-derived COX1-dependent lipid mediator and is related to TGFβ signaling.

Despite our efforts, we were unable to identify a unique platelet factor that boosts the inflammasome activation of innate immune cells. However, we show that the regulation of IL-1β production is likely mediated through a constitutively expressed protein factor that engages a CaSR on primary human macrophages. This is consistent with previous reports of roles for CaSR on inflammasome activation ([@bib59], [@bib86]). These findings will need further validation using genetic deletion of these receptors. It is possible that a combination of factors acting in synergy and affecting different pathways underlie the platelet effect.

Our findings also strengthen recent discoveries of a direct link between the mammalian immune and coagulation systems ([@bib17], [@bib105], [@bib108]) by showing a direct participation of platelets in the inflammasome output of innate immune cells.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-human Caspase-1 (p20), mAb (Bally-1)Adipogen InternationalAG-20B-0048-C100; RRID:[AB_2490257](nif-antibody:AB_2490257){#interref65}Anti-human CD14-APC (61D3)Thermo Fisher Scientific17-0149-42; RRID:[AB_10669167](nif-antibody:AB_10669167){#interref70}Anti-human CD41 FITC (HIP8)Thermo Fisher Scientific11-0419-42; RRID:[AB_10718234](nif-antibody:AB_10718234){#interref75}Anti-human CD45 PE (2D1)Thermo Fisher Scientific12-9459-42; RRID:[AB_10718238](nif-antibody:AB_10718238){#interref80}Anti-human CD66bThermo Fisher Scientific11-0666-42; RRID:[AB_2572461](nif-antibody:AB_2572461){#interref85}Anti-human NAP2 (CXCL7)PeproTech300-14-10; RRID:[AB_147531](nif-antibody:AB_147531){#interref90}Anti-human RAGER&D SystemsMAB11451; RRID:[AB_2224344](nif-antibody:AB_2224344){#interref95}Anti-mouse CD41 eFluor450 (eBioMWReg30)Thermo Fisher Scientific48-0411-82; RRID:[AB_1582238](nif-antibody:AB_1582238){#interref100}Anti-mouse CD45 PE (30-F11)Thermo Fisher Scientific12-0451-83; RRID:[AB_465669](nif-antibody:AB_465669){#interref105}Anti-human CXCL12 / SDF-1aR&D SystemsAF-310-SP; RRID:[AB_354461](nif-antibody:AB_354461){#interref110}Anti-human IL-1 beta / IL-1F2 Antibody, goatR&D SystemsAF-201-NA; RRID:[AB_354387](nif-antibody:AB_354387){#interref115}Anti-mouse IRDye 680Li-Cor Biosciences925-68080; RRID:[AB_2814917](nif-antibody:AB_2814917){#interref120}Anti-mouse Ly6G-AF488 (RB6-8C5)Thermo Fisher Scientific53-5931-82; RRID:[AB_469918](nif-antibody:AB_469918){#interref125}Anti-mouse Ly6G-APC (1A8-ly6g)Thermo Fisher Scientific17-9668-82; RRID:[AB_2573307](nif-antibody:AB_2573307){#interref130}Anti-mouse NLRP3/NALP3, mAb (Cryo-2)Adipogen InternationalAG-20B-0014; RRID:[AB_2490202](nif-antibody:AB_2490202){#interref135}Anti-human/mouse CD62p (P-selectin) APC (Psel.KO.2.3)Thermo Fisher Scientific12-0628-42; RRID:[AB_10804401](nif-antibody:AB_10804401){#interref140}Anti-human/mouse Beta-Actin (Host: mouse)Li-Cor Biosciences926-42212; RRID:[AB_2756372](nif-antibody:AB_2756372){#interref145}Anti-human/mouse Beta-Actin (Host: rabbit)Li-Cor Biosciences926-42210; RRID:[AB_1850027](nif-antibody:AB_1850027){#interref150}Anti-human/mouse Beta-Tubulin (Host: rabbit)Li-Cor Biosciences926-42211; RRID:[AB_1850029](nif-antibody:AB_1850029){#interref155}Anti-rabbit IRDye 800Li-Cor Biosciences926-32213; RRID:[AB_621848](nif-antibody:AB_621848){#interref160}FcR Blocking Reagent, humanMiltenyi Biotech130-059-901FcR Blocking Reagent, mouseMiltenyi Biotech130-092-575Mouse IgG1 K Iso Control APC (P3.6.2.8.1)Thermo Fisher Scientific17-4714-42; RRID:[AB_1603315](nif-antibody:AB_1603315){#interref165}Mouse IgG1 K Iso Control FITC (P3.6.2.8.1)Thermo Fisher Scientific11-4714-42; RRID:[AB_10596964](nif-antibody:AB_10596964){#interref170}Mouse IgG1 K Iso Control PE (P3.6.2.8.1)Thermo Fisher Scientific12-4714-42 RRID:[AB_1944423](nif-antibody:AB_1944423){#interref175}Normal Goat IgG controlR&D systemsAB-108-c; RRID:[AB_354267](nif-antibody:AB_354267){#interref180}OneComp eBeadsThermo Fisher Scientific01-1111-42Polyclonal anti-GPIb alphaEmfret AnalyticsR300; RRID:[AB_2721041](nif-antibody:AB_2721041){#interref185}Polyclonal non-immune rat immunoglobulinsEmfret AnalyticsC301; RRID:[AB_2734715](nif-antibody:AB_2734715){#interref190}Purified anti-ASC (TMS-1) AntibodyBioLegend653902; RRID:[AB_2561778](nif-antibody:AB_2561778){#interref195}Purified anti-human CD42b Antibody (HIP1)BioLegend303902; RRID:[AB_314382](nif-antibody:AB_314382){#interref200}Purified Mouse IgG, k IsotypeBioLegend401402; RRID:[AB_2801451](nif-antibody:AB_2801451){#interref205}Rat Anti-mouse CD14-FITC (Sa14-2)BioLegend123308; RRID:[AB_940580](nif-antibody:AB_940580){#interref210}Rat IgG1 K Iso Control eFluor450 (eBRG1)Thermo Fisher Scientific48-4301-82; RRID:[AB_1271984](nif-antibody:AB_1271984){#interref215}Rat IgG2a K Iso Control APC (eBR2a)Thermo Fisher Scientific17-4321-81; RRID:[AB_470181](nif-antibody:AB_470181){#interref220}Rat IgG2b, K Iso Control PE (eB149/10H5)Thermo Fisher Scientific12-4031-82; RRID:[AB_470042](nif-antibody:AB_470042){#interref225}**Chemicals, Peptides, and Recombinant Proteins**2-mercaptoethanolSigma-AldrichM6250-250MLAcetylsalicylic acid (Aspirin)Sigma-AldrichA5376-100GAcid-Citrate-dextrose solution (ACD)Sigma-AldrichC3821-50MLAdenosine 5-diphosphate sodium salt (ADP)Sigma-AldrichA2754-500MGAdenosine triphosphate (ATP)Sigma-AldrichA2382Apyrase from potatoes, High Activity, ATPase \> 600 units/mg proteinSigma-AldrichA2230-100UNBAPTA AMEnzo Life Sciences IncBML-CA411-0025BAPTA, Tetrasodium saltSanta Cruz Biotechnologysc-278716Benzonase® NucleaseSigma-AldrichE1014-5KUBovine Serum Albumin (BSA)Sigma-AldrichA9647Calcium chlorideSigma-Aldrich21115-100MLChloroformMerck1.02445.1000cOmplete EDTA-free protease inhibitor Cocktail TabletsSigma-Aldrich4693132001CRID3 (CP-456773-02, MCCP90)Sigma-AldrichPZ0280Cutasept® F Haut-DesinfiziensHartmann9803640Cytochalasin DSigma-AldrichC8273-1MGD-(+)-Glucose solutionSigma-AldrichG7021-100 gDi-Sodium hydrogen phosphate (Na~2~HPO~4~)Sigma-Aldrich255793Dimethyl sulfoxide (DMSO), cell culture gradePAN-BiotechP60-36720100Dithiothreitol (DTT)Thermo Fisher ScientificY00147dNTP Mix (10 nM each)Thermo Fisher ScientificR0192DRAQ5Thermo Fisher Scientific65-0880-96Ethanol (EtOH) absoluteAppliChem147194.1214Fetal Bovine Serum (FBS)Thermo Fisher Scientific26140079Ficoll-Paque PLUSGE Healthcare17-1440-03GIBCO Dulbecco's Dulbecco's Modified Eagle Medium (DMEM)Thermo Fisher Scientific41965039GIBCO Dulbecco's Phosphate Buffered Saline (PBS)Thermo Fisher Scientific14190144GIBCO GlutaMAX 100XThermo Fisher Scientific35050061GIBCO Penicillin-Streptomycin (10,000 U/mL)Thermo Fisher Scientific15140122GIBCO RPMI 1640 MediumThermo Fisher Scientific21875091GIBCO Sodium Pyruvate 100mMThermo Fisher Scientific11360070GIBCO UltraPure 0.5M EDTA, pH 8.0Thermo Fisher Scientific15575020Hoechst 34580Thermo Fisher ScientificH21486L929 cell line supernatantGift from Prof. Latz and Ms. Engels (University of Bonn)N/ALipopolysaccharide (LPS), ultrapure, *E. coli* 0111:B4Invivogentlrl-3pelpsMagnesium chloride (MgCl~2~) solutionSigma- AldrichM1028-100MLMethanolMerck1.06007.2500Met-RANTES trifluoroacetate salt, humanBachemH-6544.0050Nigericin, free acidInvitrogenN1495Oligo(dT)~18~ primerThermo Fisher ScientificSO132PageRuler™ Plus Prestained Protein Ladder, 10 to 250kDaThermo Fisher Scientific26619Pam3Cysk4InvivoGenP2200.0005PhosSTOP Easypack Phasphatase Inhibitor Cocktail TabletsSigma-Aldrich04906837001Piperazine-1,4-bis(2ethanesulfonic acid) (PIPES)Sigma-AldrichP6757-25GPoly-L-Lysine solutionSigma-AldrichP4707Potassium chloride (KCl)Sigma-AldrichP9327-100ML(LFn-)PrgI fusion proteinGift from Prof. Geyer and Dr. Fußhöller (University of Bonn)N/AProstaglandin E1 (PGE-1)Sigma-AldrichP5515-1MGProtective antigen (PA), recombinant from *Bacillus anthracis*List Biological Laboratories171CR848Invivogentlrl-r848-5Recombinant human BDNFTocris Bioscience2837Recombinant human CD40L / CD154, solubleEnzo Life SciencesALX-522-015-C010Recombinant human EGFSigma-AldrichE9644Recombinant human GM-CSFImmunotools11343125Recombinant human GRO-alpha / MGSA (CXCL1)PeproTech300-11-5UGRecombinant human NAP-1 (CXCL7)PeproTech300-14-10Recombinant human P-selectinR&D systemsADP3Recombinant human PF4 (CXCL4)PeproTech300-16-5UGRecombinant human PGDF-BBBioLegend577304Recombinant human PLGF-1 (PIGF-1)Thermo Fisher ScientificPHG0296Recombinant human RANTES (CCL5)Thermo Fisher ScientificPHC1054Recombinant human S100A8/S100A9 heterodimerR&D Systems8226-S8-050Recombinant human SDF-alpha (CXCL12)PeproTech300-28a-10UGRecombinant human TGF-b1PeproTech100-21C-2UGRecombinant human THBS-1Sigma-AldrichECM002-50UGRecombinant human VEGFThermo Fisher ScientificPHC9394SB431542Invivogeninh-sb43Sodium chloride (NaCl)Sigma- AldrichS5150-1LSodium deoxycholateSigma- AldrichD-6750-10GSodium dodecyl sulfate (SDS)Sigma- Aldrich75746-1KGSodium hydroxide (NaOH)Sigma- AldrichS2770-100MLSulfo-N-succinimidyl Oleate sodium (SSO)BioMolCay11211-5TAK242 (Resatorvid)Invivogentlrl-cli95Thrombin from human plasmaSigma-AldrichT6884-100UNTriton X-100Carl Roth3051.3Tween® 20Sigma- AldrichP2287UK5099BioMolCay16980-5Wheat Germ Agglutinin (WGA) Alexa Fluor 555Thermo Fisher ScientificW32464ZileutonTocris3308GIBCO Opti-MEMThermo Fisher Scientific31985070Lipofectamine 2000 Transfection ReagentThermo Fisher Scientific11668019Poly \[dA:dT\]SigmaP0883**Critical Commercial Assays**Alexa Fluor 647 Antibody labeling kitThermo Fisher ScientificA20186Caspase-Glo® 1 Inflammsome AssayPromegaG9952CD14 MicroBeads, humanMiltenyi Biotech130-050-201EasySep Direct Human Neutrophil Isolation KitSTEMCELL Technologies19666EasySep Human Monocyte Isolation KitStemcell19359Human IL1 beta HTRF kitCisbio62IL1PEBHuman TNF alpha HTRF kitCisbio62TNFPEBMaxima SYBR Green/ROX qPCR Master MixThermo Fisher ScientificK0221Mouse IL1 beta HTRF kitCisbio63ADK010PEBMouse IL6 HTRF kitCisbio63ADK043PEBMouse TNF alpha HTRF kitCisbio6FMTNPEBPierce BCA Protein Assay KitThermo Fisher Scientific23225Pierce LDH Cytotoxicity Assay KitThermo Fisher ScientificB3026-88954ProcartaPlex Human Cytokine/Chemokine/Growth Factor Panel 1 45plexThermo Fisher ScientificEPX450-12171-901RNase-Free DNase SetQIAGEN79254RNeasy Mini KitQIAGEN74106S-Monovette 9NC tubesSarstedt01.1606.001S-Monovette K3EDTA tubesSarstedt02.1066.001SuperScript III First-Strand Synthesis SuperMixThermo Fisher Scientific18080-400**Deposited Data**Transcription profiling of whole blood from pediatric patients Muckle-Wells disease and healthy childreen[@bib8]Accession Nr.: GSE43553Transcription profiling of human platelets from patients with essential thrombocythemia[@bib41]Accession Nr.: E-GEOD-2006Transcription profiling of human platelets from patients with dengue shock syndrome[@bib30]Accession Nr.: GEOD17924Transcription profiling of human platelets from patients with sickle cell disease[@bib83]Accession Nr.: E-GEOD-11524Transcription profiling of human platelets from patients with sepsis-induced acute lung injury (ALI)[@bib113]Accession Nr.: E-GEOD-10361Transcription profiling of human platelets from patients with Polycythemia Vera (PV)[@bib93]Accession Nr.: E-GEOD-47018Raw Mass Spectrometry Data FilesThis paperData are available via ProteomeXchange: [PXD017976](pdb:PXD017976){#interref230}**Experimental Models: Cell Lines**NLRP3-FLAG overexpressing immortalized NLRP3 KO([@bib112], [@bib96])THP-1ATCCATCC TIB-202MEG01ATCCCRL2021**Experimental Models: Organisms/Strains***Mus musculus*, wild-type (C57BL/6j)The Jackson LaboratoryStock 000664*Mus musculus*, ASC-mCitrine Tg (B6.Cg-Gt(ROSA)26Sortm1.1(CAG-Pycard/mCitrine^∗^,-CD2^∗^)Dtg/J)The Jackson LaboratoryStock 030744*Mus musculus*, *Nlrp3*^--/--^ mice (B6.B6N-Nlrp3tm1Vmd)[@bib70]N/A*Mus musculus*, *Asc*^*--/--*^ mice (B6.129-Pycardtm1Vmd)[@bib69]N/A*Mus musculus*, *Il1b*^*--/--*^ mice (B6.129S2-Il1btm1Dch)[@bib91]N/A*Mus musculus*, *Il1r*^*--/--*^ mice (B6.129S7-Il1r1tm1Imx/J)The Jackson LaboratoryStock 003245*Mus musculus*, *Il18r*^*--/--*^ mice (B6.129P2-Il18r1tm1Aki/J)The Jackson LaboratoryStock 004131*Mus musculus*, *Cd36*^*--/--*^ mice (B6.129S1-Cd36tm1Mfe/J)The Jackson LaboratoryStock 019006*Mus musculus*, *Tsp1*^*--/--*^ mice (B6.129S2-Thbs1(tm1Hyn)/J)The Jackson LaboratoryStock 006141*Mus musculus*, *Cxcr3*^*--/--*^ mice (B6.129P2-Cxcr3tm1Dgen/J)The Jackson LaboratoryStock: 005796*Mus musculus*, *Ccr5*^*--/--*^ mice (B6.129P2-Ccr5tm1Kuz/J)The Jackson LaboratoryStock: 005427The knock in ASC-mCherry reporter mouse is available upon requestEicke Latz, Institute of Innate ImmunityN/A**Oligonucleotides**hACTB-Fwd: 5′-ccaccatgtaccctggcatt-3′MetabionN/AhACTB-Rev: 5′-cggagtacttgcgctcagga-3′MetabionN/AhNLRP3-Fwd: 5′-tcggagacaaggggatcaaa-3′MetabionN/AhNLRP3-Rev: 5′-agcagcagtgtgacgtgagg-3′MetabionN/AhCD14-Fwd: 5′-gagctcagaggttcggaaga-3′MetabionN/AhCD14-Rev: 5′-cttcatcgtccagctcacaa-3′MetabionN/AhPYCARD-Fwd: 5′-gagctcaccgctaacgtgct-3′MetabionN/AhPYCARD-Rev: 5′-actgaggaggggcctggat-3′MetabionN/AhPF4- Fwd: 5′-ctgaagaagatggggacctg-3′MetabionN/AhPF4- Rev: 5′-gtggctatcagttgggcagt-3′MetabionN/AhCASP1-Fwd: 5′-acaacccagctatgcccaca-3′MetabionN/AhCASP1-Rev: 5′-gtgcggcttgacttgtccat-3′MetabionN/AhBP1BA-Fwd: 5′-ctgctctttgcctctgtggt-3′MetabionN/AhBP1BA-Rev: 5′-ctccaggtgtgtggtttgtg-3′MetabionN/AhIL1B-Fwd: 5′-tgggcagactcaaattccagct-3′MetabionN/A**Software and Algorithms**GraphPad Prism 8.1.2 (227)<https://www.graphpad.com>RRID:[SCR_002798](rridsoftware:SCR_002798){#intref0015}FlowJo 10.4<https://www.flowjo.com>RRID:[SCR_008520](rridsoftware:SCR_008520){#intref0025}Volocity 3D Image Analysis Software v6.0.1<https://www.perkinelmer.com>RRID:[SCR_002668](rridsoftware:SCR_002668){#intref0035}

Resources Availability {#sec4.2}
----------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bernardo S Franklin (<franklin@uni-bonn.de>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents. The knockin ASC-mCherry reporter mouse is available upon request.

### Data and Code Availability {#sec4.2.3}

The mass spectrometry proteomics data are available via ProteomeXchange: [PXD017976](pdb:PXD017976){#interref235}.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Study Subjects {#sec4.3.1}

Peripheral blood was obtained by venipuncture of healthy volunteers after signature of informed consent, and approval of the study by the Ethics Committee of the University of Bonn (Protocol \#282/17), and in accordance with the Declaration of Helsinki.

Malaria patients naturally infected with *Plasmodium vivax* in the Amazon area of Cuiaba (Mato Grosso, Brazil) were invited to participate in the study. Seventy-eight individuals (aged 18 - 78 years old) who sought care at the Julio Muller Hospital, whose thick blood smear was positive for *P. vivax* were included. Another 9 healthy volunteers from the same endemic area who tested negative for Plasmodium infection were recruited and served as healthy donor controls. Exclusion criteria included: (i) refuse or inability to sign the informed consent; (ii) age \< 18 years; (ii) pregnant women; (ii) mixed infection with *P. falciparum* or *P. malariae*, tested by both microscopic examination and a nested-PCR; (iv) any other comorbiditythat could be traced. Clinical and demographical data were acquired through a standardized questionnaire, and the hematological profiles were assessed by automated complete blood count carried out at the site hematology facility. Plasma samples were isolated immediately after blood sampling and stored at −80°C until use. The study was approved by the Ethical Review Board of the René Rachou Research Center, FIOCRUZ, Brazilian Ministry of Health (Reporter CEPSH/CPqRR N. 05/2008 and N. 01/2018).

All participants were instructed about the objectives of the study and signed an informed consent in accordance with guidelines for human research, as specified by the Brazilian National Council of Health (Resolution 196/96). Patients diagnosed with *P. vivax* malaria were treated according to the standard protocols recommended by the National Malaria Control Program (chloroquine + primaquine).

### Mice {#sec4.3.2}

Mice were housed under standard conditions at 22°C and a 12 h light-dark cycle with free access to food and water. Animal care, handling and experimentation was approved by the ethical committee in Bonn: LANUV-NRW \#84-02.04.2016.A487), and in Ribeirão Preto, São Paulo (149/2019). Male 8 -- 12 week old C57BL/6j mice were used for experimentation. Male and female 8 week old C57BL/6j, *Nlrp3*^--/--^, *Asc*^--/--^, *Casp-1*^--/--^, *Il1b*^--/--^, *IL1r*^--/--^, *IL18r*^--/--^, *Tsp1*^*--/--*^, *Cd36*^*--/--*^, *Cxcr3*^*--/--*^*, Ccr5*^*--/--*^, and ASC-mCitrine Tg mice were used as source of primary cells.

### Cell lines {#sec4.3.3}

The monocytic cell line THP-1 (ATCC TIB-202), and the megakaryocytic cell line MEG-01 (ATCC CRL-2021) were cultured in RPMI-1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin and GlutaMAX (1x) at 37°C with 5% CO~2~.

Methods Details {#sec4.4}
---------------

### Data Presentation {#sec4.4.1}

Unless indicated otherwise (in Figure legends), all graphs are represented as Floating Bars (with mean, and minimum to maximum values) and are built from pooled data from a minimum of two independent experiments (biological replicates), performed in triplicates (technical replicates) with immune cells or platelets from different donors. For experiments performed less than 3 times, bar graphs with mean and standard deviation (SD) are shown. Each symbol represents the average from 3 technical replicates per each donor, experiment, or mouse. Symbols are coded (●, □, ▴, ▾, etc.) to indicate donors so readers can track the internal variability between different donors, mice, or experiments. Dots are semi-transparent, with darker symbols indicating overlapping points.

### Generation of human primary macrophages {#sec4.4.2}

Buffy coats from healthy donors were obtained according to protocols accepted by the institutional review board at the University of Bonn (local ethics votes Lfd. Nr. 075/14). Primary human macrophages were obtained through differentiation of CD14+ monocytes in a medium complemented with 500 U ml^-1^ rhGM-CSF (Immunotools) for 3 days. In brief, human peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats of healthy donors by density gradient centrifugation in Ficoll-Paque PLUS (Healthcare). PBMCs were incubated at 4°C with magnetic microbeads conjugated to monoclonal anti-human CD14 antibodies according to the manufacturer's instructions (Miltenyi Biotech). CD14+ monocytes were thereby magnetically labeled and isolated using a MACS column placed in a magnetic field. CD14+monocytes were cultivated in complete medium (RPMI1640 medium with 10% FBS, 1% Penicillin-Streptomycin, 1% GlutaMAX and 1% Sodium Pyruvate) complemented with 500 U ml^-1^ rhGM-CSF at a concentration of 2x10^6^ ml^-1^ in 6-well plates to generate monocyte-derived macrophages. Cells were harvested at day 3, counted using a hemocytometer and seeded at a concentration of 1x10^5^/well in complete medium complemented with 125 U ml^-1^ rhGM-CSF in 96-well flat-bottom plates and incubated overnight for experiments on the next day.

### Generation of mouse bone marrow macrophages {#sec4.4.3}

Mice were anaesthetized and sacrificed by cervical dislocation. Femur and tibia from hind limbs were removed and the bones were briefly disinfected with 70% ethanol. The bone marrow cavity was flushed with PBS and the cell suspension was filtered through a 70 μm cell strainer before centrifugation at 400 x g for 5 minutes. Cells were resuspended in DMEM supplemented with 20% L929 supernatant and cultured for 6 days to differentiate into macrophages (BMDMs). On day six, cells were harvested using cold PBS containing 5 mM EDTA and 2% FBS and scraping. After centrifugation at 350 x g for 5 minutes, the BMDM were seeded at 1x10^5^/well in DMEM with 20% L929 supernatants in flat-bottom 96-well plates and incubated overnight for experiments on the next day.

### Isolation of CD14^+^ human Monocytes {#sec4.4.4}

Venous blood was collected in S-Monovette® K3EDTA tubes and PBMCs were obtained by density gradient centrifugation in Ficoll-Paque PLUS. Monocytes were isolated from PBMCs using the EasySepTM Human Monocyte Isolation Kit according to the manufacturer instructions (STEMCELL Technologies™). PBMCs were washed twice with PBS complemented with 2% FBS and 1mM EDTA before incubated with the supplied monocyte isolation cocktail and the platelet removal cocktail for 5 minutes. Magnetic beads were added to this suspension for another 5 minutes before magnetic separation in an EasySepTM Magnet. After 2.5 minutes of incubation, the enriched suspension was poured into a new tube. The isolated monocytes were counted using a hemocytometer and resuspended in RPMI medium at a concentration of 1x10^6^ ml^-1^. The purity of the purified monocytes was assessed by flow cytometry using CD14 (monocyte) and CD41 (platelet) markers.

### Isolation of Human Neutrophils {#sec4.4.5}

Venous blood was collected in S-Monovette® K3EDTA tubes and neutrophils were isolated using the EasySep™ Direct Human Neutrophil Isolation Kit according to the manufacturer instructions (STEMCELL Technologies™). Whole blood was incubated with the Neutrophil Isolation Cocktail and RapidSpheres™ for 5 minutes and diluted with neutrophil isolation buffer (1mM EDTA in PBS). After 5 minutes of incubation in the EasySep™ Magnet, the enriched cell suspension was poured into a new tube and incubated again with RapidSpheresTM for another 5 minutes, followed by a second, and third round of magnetic separation. The obtained neutrophils were counted using a hemocytometer and pelleted by centrifugation at 350 x g for 5 minutes. Cells were resuspended in RPMI-1640 medium supplemented with 10% FBS, 1% GlutaMAX and 1% Penicillin-Streptomycin. Neutrophil suspension was adjusted to 1x10^6^ ml^-1^ and 100 μL (1x10^5^cells/well) were seeded in a 96-well round-bottom plate. The purity of the purified neutrophils was assessed by flow cytometry using CD66b (neutrophil marker) and CD41 (platelet marker).

### Isolation of Human Platelets {#sec4.4.6}

Human platelets were isolated as previously described ([@bib1]) with slight modifications. In brief, venous blood was drawn into S-Monovette® 9NC collection tubes. The blood was centrifuged for 5 minutes at 330 x g without brake to obtain platelet-rich plasma (PRP). All following centrifugation steps were performed without brake and in the presence of 200 nM PGE1 to inhibit platelet activation. PRP was transferred to a new tube and diluted 1:1 with phosphate-buffered saline (PBS) to reduce leukocyte contamination and centrifuged for 10 minutes at 240 x g. Platelets were pelleted by centrifugation at 430 x g for 15 minutes and washed once with PBS. Total platelets were counted using a hemocytometer and resuspended in RPMI medium to a concentration of 1x10^8^ ml^-1^ unless otherwise indicated. The purity of the purified platelets was assessed by flow cytometry using CD45 (leukocyte) and CD41 (platelet) markers.

### Isolation of Mouse Platelets {#sec4.4.7}

Blood was drawn by puncturing the vena facialis of anaesthetized mice. Blood from mice of the same genotype were pooled in a sterile 5 mL polystyrene tube containing one-sixth blood volume of pre-warmed citrate-dextrose solution (ACD). PRP was prepared by centrifugation at 330 x g for 5 minutes without break. All following centrifugation steps were performed without brake. PRP was transferred to a new tube and diluted in twice as much volume of PIPES/saline/glucose (PSG) buffer with the final concentration of 1.5 μM PGE~1~. The suspension was centrifuged at 240 x g for 10 minutes to reduce leukocyte and erythrocyte contamination. The supernatant was transferred into a tube with PGE~1~ in a final concentration of 0.7 μM in PSG buffer. The platelets were pelleted by centrifugation at 1000 x g for 5 min, washed with 1.5 μM PGE~1~ in PSG buffer. The washed platelets were resuspended in DMEM, counted in a hemocytometer, and the platelet suspension was adjusted to 5x10^6^ ml^-1^ unless otherwise indicated. Purity and viability of the prepared platelets were assessed by flow cytometry.

### Purity Assessment of Cells Populations {#sec4.4.8}

Samples of isolated neutrophils and platelets were analyzed for purity, platelet pre-activation and platelet viability after each experiment. Isolated murine and human platelets were activated with 0.5 or 1 U ml^-1^ thrombin respectively for 30 min. Cells were blocked with 1:10 mouse or human Fc blocking reagent for 10 minutes at room temperature (RT). The samples were stained with fluorochrome-conjugated monoclonal anti-mouse or anti-human Ig antibodies against CD41/CD41, CD62p, CD14, CD45 or CD66b as indicated for 30 minutes in the dark. Cells were washed and resuspended in flow cytometry buffer (1% FBS in PBS) for analysis. Compensation beads (OneComp Beads) and isotype controls were prepared in the same way. Flow cytometry was performed with a Macs Quant® Analyzer10 (Miltenyi Biotech) and analyzed using the Flowtop software (Tree Star). The applied gating strategy was based on doublet discrimination and isotype-matched control antibodies.

### Platelet depletion and LPS + R848 model {#sec4.4.9}

Platelet depletion was performed in male, 6-10 week-old C57BL/6j mice by intravenous injection of an anti-CD42b (GPIb-alpha) monoclonal antibody or its isotype IgG control (Emfret Analytics, 2 μg/g animal, 100 μL). 6 hours after injection, a drop of blood was taken from the tail vein to confirm the efficiency of platelet depletion by flow cytometry. Next, the animals were intraperitoneally injected with 200 μg of R848 (Resiquimod, Invivogen) or a combination of 200 μg of R848 and 200 μg of LPS (E.coli O111:B4, Invivogen) in equal volumes (100 μL) as described ([@bib51]). The collection of samples was conducted 6 hours after the inflammatory stimuli. Blood was centrifuged for 10 minutes at 5000 rpm, 4°C for collection of serum. Peritoneal lavage was centrifuged for 5 minutes at 500 g, 4°C and the cells from the peritoneal lavage were fixed and stained for phenotyping. Blood and cell-free peritoneal exudate were used for the cytokine evaluation (R&D Systems).

### Immuno-staining of Whole Bone Marrow Cells {#sec4.4.10}

Wild-type, ASC-mCitine Tg or ASC-mCherry *knock in* reporter mice were anesthetized with isoflurane and sacrificed by cervical dislocation. Femurs and tibias from hind limbs were removed and the bones were briefly disinfected with 70% ethanol. The bone marrow cavity was flushed with PBS and the cell suspension was filtered through a 70 μm cell strainer before centrifugation (400 x g, 5 minutes). Cells were resuspended in staining buffer and blocked with 1:10 mouse FcR blocking reagent for 10 minutes at RT before staining with fluorochrome-conjugated anti-mouse CD41 (platelet marker), Ly6G (neutrophil marker), CD14 (monocyte marker) or CD45 (leukocyte marker) (1:5 dilution each). Staining was performed for 30 min at room temperature. Cells were washed twice in PBS and resuspended in staining buffer before flow cytometry analysis or confocal microscopy imaging. Compensation beads (OneComp eBeads) and isotype controls were prepared in the same way. Flow cytometry was performed on MacsQuant® VYB and analyzed using FlowJo. The gating strategy was based on doublet discrimination and isotype-matched control antibodies or unstained controls.

### Generation of Platelet and MK supernatants {#sec4.4.11}

After platelet isolation, the cell suspension was adjusted to 5x10^7^ platelets ml^-1^ (for human experiments) or 5x10^6^ platelets ml^-1^ (for mouse BMDM experiments), in order to fit the macrophage:platelets proportion of 1:50 (human) or 1:5 (mouse). For the generation of supernatants from the megakaryocytic cell line MEG-01, 1x10^6^ cells ml^-1^ were used. Next, platelets or MEG-01 were left untreated (Unstim) or incubated at 37°C with LPS (200 ng ml^-1^) or thrombin (1.0 U ml^-1^) for 3 hours. After stimulation, the platelet cell suspension was centrifuged for 10 minutes at 3000 x g for the generation of the cell-free supernatants. MEG-01 cells were first centrifuged for 7 minutes at 170 x g and the obtained supernatants were centrifuged again for 10 minutes at 3000 x g. The absence of cells was confirmed by microscopic visualization in a hemocytometer. The supernatants were immediately used to stimulate hMDMs in RPMI, or immediately frozen at −80°C until further use.

### Stimulation of THP-1 and MEG-01 cells {#sec4.4.12}

For stimulation assays, THP-1 cells were treated overnight with 100 nM phorbol 12-myristate 13-acetate, then were primed for 2 h with 1 μg ml^-1^ of LPS and were subsequently activated with 10 μM of Nigericin.

### Stimulation assays {#sec4.4.13}

Seeded BMDMs, human macrophages or neutrophils were centrifuged at 350 x g for 5 minutes prior to replacing the supernatant by fresh, serum-free DMEM (for BMDMs) or RPMI (for human neutrophils and macrophages) as control or platelet suspension. For NLRP3 stimulation, cells were primed with 200 ng ml^-1^ LPS for 3 hours and activated with 10 μM Nigericin or 5 mM ATP for 90 minutes unless otherwise indicated. Human monocytes were primed with 2 ng ml^-1^ of LPS before being activated with Nigericin (10 μM, 90 min).

For the stimulation of the NLRC4 inflammasome, human macrophages were primed with 200 ng ml^-1^ LPS for 3 hours before 2 μg ml^-1^ LFn-PrgI and 0.5 μg ml^-1^ PA (from *Bacillus anthracis*) were added to the culture medium for 2 hours ([@bib110]).

For the stimulation of the AIM2 inflammasome, human GM-CSF-derived macrophages were primed with LPS (200 ng ml^-1^, 3 hours), followed by stimulation with transfected Poly(dA:dT). Briefly, vesicles were formed using a 1:50 dilution of the transfection agent Lipofectamine 2000 in OptiMEM. After 15 minutes of incubation, the empty vesicles were combined in 1:1 proportion of 4 μg ml^-1^ Poly(dA:dT), and further incubated for 15 minutes. The dsDNA-containing vesicles were added directly on the cell culture for a final volume of 100 μl of medium (final stimulatory concentration of 1 μg ml^-1^). Cells were stimulated for 3 hours before cell-free supernatants were harvested for cytokine measurements.

R848 and Pam3Cysk4 were also used for priming in some experiments at 10 μM and 1 μg ml^-1^ respectively. After stimulation, cells were centrifuged and cell-free supernatants were collected to measure cytokine levels by HTRF. In experiments where the activity of COX1/2 and LOX was inhibited, platelets were incubated with Aspirin, or Zileuton (both at 100 μM) for 60 min at 37°C, before their addition to hMDMs. SB-431542 (10 μM) was added to the macrophage culture 60 minutes before stimulation. The drugs were diluted in RPMI 1640, without supplements.

### Trans-well assays {#sec4.4.14}

HMDMs were seeded at a concentration of 1 × 10^5^/100 μL in HTS 0.4 μm Trans-well 96-well plates on the day prior to the experiment. Platelets were added to the upper wells at a concentration of 6.25 × 10^7^ in 80 μL of DMEM. After addition of platelets, inflammasome activation was carried out as described above and the levels of IL-1β and TNFα were assessed in cell-free supernatants by HTRF.

### Calcium chelation experiments {#sec4.4.15}

The calcium chelator BAPTA or the cell-permeable calcium chelator BAPTA-AM (see [STAR Methods](#sec4){ref-type="sec"}) were used to examine extracellular and intracellular calcium involvement respectively. hMDMs were seeded in RPMI medium (for BAPTA-AM treatment) or in calcium-free medium (for BAPTA treatment) with or without platelets as described before. Cells were primed with 200 ng ml^-1^ LPS for 3 hours before the addition of either 0.5 mM BAPTA or 5 μM BAPTA -AM. Then, cells were stimulated with 10 μM Nigericin for NLRP3 Inflammasome activation. Cell-free supernatants were analyzed afterward by HTRF for cytokine secretion.

### Quantitative PCR {#sec4.4.16}

Total RNA containing small RNAs from purified human platelets, or PBMCs was purified using the miRNeasy kit (QIAGEN), DNA was digested with DNase I (QIAGEN), and cDNA was generated by using 500 ng RNA with SuperScript III Reverse Transcriptase kit (Thermo Fisher) following the manufacturer's instructions. cDNA was diluted (1:10 for PBMCs, and 1:3 for platelets) and qPCR was performed with Maxima SYBR Green on a QuantStudio 6 Flex RT PCR machine (Thermo Fisher) for 40 cycles and followed by a melt curve analysis for off-target products. The primers used were *ACTB*-fwd-ccaccatgtaccctggcatt, ACTB-rev-cggagtacttgcgctcagga, NLRP3-fwd-tcggagacaaggggatcaaa, NLRP3-rev-agcagcagtgtgacgtgagg, CD14-fwd-gagctcagaggttcggaaga, CD14-rev-cttcatcgtccagctcacaa, PYCARD-fwd-gagctcaccgctaacgtgct, *PYCARD*-rev-actgaggaggggcctggat, PF4-fwd-ctgaagaagatggggacctg, PF4-rev-gtggctatcagttgggcagt, CASP1-fwd-acaacccagctatgcccaca, CASP1-rev-gtgcggcttgacttgtccat, GP1BA-fwd-ctgctctttgcctctgtggt, GP1BA-rev-ctccaggtgtgtggtttgtg, IL1B-fwd-tgggcagactcaaattccagct, IL1B-rev-ctgtacctgtcctgcgtgttga.

### Imaging and quantification of ASC specks {#sec4.4.17}

To examine ASC specking, hMDMs were seeded at a concentration of 2 × 105/well in 8-well IBIDI μ-slide one day prior to the experiment. Freshly isolated platelets were added to hMDMs on the day of the experiment at a concentration of 5 × 107 ml^-1^. Cells were stimulated with 200 ng ml^-1^ LPS for 3 hours and the NLRP3 inflammasome was activated with 10 μM Nigericin for 45 minutes. Afterward, the plate was centrifuged (500 x g, 5 minutes) and the cells were fixed with 4% paraformaldehyde in PBS for 10 minutes on ice. After two washes with PBS, cells were blocked with 1:10 human FcR blocking reagent for 10 minutes at room temperature and stained with directly labeled anti-ASC-647 or the same amount of directly labeled IgG1 control and incubated overnight at 4°C in the dark (section 3.1.6). On the next day, cells were washed twice with permeabilization buffer (500 x g, 5 minutes) before staining with the DNA dye Hoechst (1:3000 dilution) in PBS for 10 minutes at RT in the dark. After two subsequent washes with PBS, cells were resuspended in PBS and imaged using an Observer.Z1 epifluorescence microscope, 20 × objective (dry, PlanApochromat, NA 0.8; ZEISS, Oberkochen, Germany), Axiocam 506 mono, and ZEN Blue software (ZEISS, Oberkochen, Germany). Representative images were taken using a Leica TCS SP5 SMD confocal system. The quantification of ASC specks per nuclei was carried out using the image analyzer software CellProfiler 3.0 (Open source software: <https://cellprofiler.org>). A pipeline was constructed to convert the fluorescent images into binary code. Through this conversion, the nuclei and ASC specks were identified and quantified. ASC specks were identified using the EnhanceFeature tool.

### Cytokine measurements {#sec4.4.18}

Levels of human, or murine IL-1β, IL-6, and TNFα in cell-free supernatants were quantified using commercially available HTRF® (homogeneous time-resolved fluorescence) kits. The HTRF was performed according to manufacturer instructions (Cisbio). Multiplex Cytokine array was used for the detection of several human cytokines and growth factors according to the manufacturer's instructions (Thermo Fisher).

### Caspase-1 activity {#sec4.4.19}

Caspase-Glo® 1 Inflammasome Assay (Promega) provides a luminogenic caspase-1 substrate, Z-WEHD-amino luciferin, in a lytic reagent optimized for caspase-1 activity and luciferase activity. The reaction buffer was mixed with the cell-free supernatant and the luminescent signal was evaluated 30 minutes later.

### Lactate dehydrogenase (LDH) assay {#sec4.4.20}

The extracellular lactate dehydrogenase (LDH) concentrations in cell-free supernatants were assessed using the Pierce LDH Cytotoxicity Assay, according to the manufacturer's instructions. Samples were measured at an absorbance of 490 nm using a Spectramax i3 plate reader (ThermoFisher). Control hMDMs cultured at the same conditions as the samples were lysed with the provided Lysis buffer (10x) and served as positive control for maximal LDH release.

### Confocal laser scanning microscopy {#sec4.4.21}

Platelets and immune cells were imaged in a Leica TCS SP5 SMD confocal system (Leica Microsystems, Wetzlar, Germany). Images were acquired using a 63X objective, with a numerical aperture of 1.2, and analyzed using the Volocity 6.01 software (PerkinElmer, Waltham, Massachusetts, U.S.A.).

### Meta-analysis of microarray data {#sec4.4.22}

Pre-processed microarray data of platelets and whole peripheral blood cells under steady state and certain disease states (GSE2006, GSE11524, GSE10361, GSE50858, GSE47018, GSE17924) were down-loaded from the Gene Expression Omnibus (GEO) data base (<https://www.ncbi.nlm.nih.gov/geo/>). Expression values for the house-keeping gene GAPDH and platelet- as well as inflammasome-associated genes (*CXCL4*/*PFA4*, *PDGFA*, *IL1B*, *PYCARD*, *NLRP3*, *TIMP1 CASP1*, *ARG2*, *TP2A*, *SELENB1*) were extracted for each dataset. In case multiple probe sets for GAPDH were present on the microarray chip, a mean expression value for GAPDH was calculated. The expression values for probe sets of platelet and inflammasome-associated genes were normalized for each dataset according to the respective GAPDH mean expression value. Log2 transformed normalized expression data were plotted as bar charts by the Tidyverse package in R (v3.4.2).

### Proteomics (LC-MS) {#sec4.4.23}

Suspensions of freshly isolated human platelets were adjusted to a concentration of 5x10^7^ ml^-1^ in RPMI. Platelets were left untreated, or stimulated with 200 ng ml^-1^ LPS, 1 U ml^-1^ Thrombin for 3 hours. Platelets were pelleted by centrifugation (3000 x g, 10 minutes) and the cell-free supernatants were harvested. Cell-free supernatants were added with 1x complete protease inhibitor cocktail prior to freezing at −80°C. Proteomics analysis was carried out at the CECAD/CMMC Proteomics Core Facility (University Cologne, Germany) on a Q Exactive Plus Orbitrap (Thermo Scientific) mass spectrometer that was coupled to an EASY-nLC (Thermo Scientific). Briefly, peptides were loaded in 0.1% formic acid in water onto an in-house packed analytical column (50 cm ó 75 μm I.D., filled with 2.7 μm Poroshell EC120 C18, Agilent) and were chromatographically separated at a constant flow rate of 250 nl/minute with the following gradient: 3%--4% solvent B (0.1% formic acid in 80 % acetonitrile) within 1 minute, 4%--27% solvent B within 119 minute, 27%--50% solvent B within 19 minutes, 50%--95% solvent B within 1 minutes, followed by washing and equilibration of the columns. The mass spectrometer was operated in data-dependent acquisition mode. All mass spectrometric raw data were processed by the CECAD/CMMC Proteomics Core Facility using Maxquant (version 1.5.3.8) with default parameters. Briefly, MS2 spectra were analyzed against the Uniprot HUMAN. fasta (downloaded at: 16.6.2017) database, including a list of common contaminants. False discovery rates on protein and PSM level were estimated by the target-decoy approach to 1% FDR for both. The minimal peptide length was determined to be 7 amino acids and carbamidomethylation at cysteine residues was considered as a fixed modification. Oxidation and acetylation were included as variable modifications. For the analysis, the match-between runs option was enabled. Label-free quantification (LFQ) was activated using default settings. Figures were assembled using the R Tidyverse package. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE \[1\] partner repository with the dataset identifier PXD017976.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analyses were performed with GraphPad Prism Version 7.0f. All statistical analysis were preceded by Normality tests, followed by the recommended parametric or nonparametric tests. For most *in vitro* experiments with several groups (hMDMs alone versus with Platelets, stimulated or not), P values were determined by two-way ANOVA with Tukey's or Sidak's or multiple comparison tests. For *in vivo* experiments, in which two groups of mice are compared (n = 6/group), ([Figure 3](#fig3){ref-type="fig"}) we used two-tailed Unpaired t test to calculate differences. Correlations between cytokines and cell counts were computed with Two-tail Spearman. Outliers were detected using the ROUT method, and were excluded from the statistical analysis, but not removed from the figures. Additional statistical details are given in the respective figure legends, when appropriate.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S7 and Table S1Document S2. Article plus Supplemental Information
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